Archive for September 17th, 2009

With over $41 million raised, five regional research and training centres launched and a growing number of educational events aimed at MS researchers and trainees, the Multiple Sclerosis Society of Canada proudly marked one year since the launch of its endMS capital campaign. “The achievements since the

Data from two long-term open-label extension studies of Fampridine-SR show that 86.0% of participants remained on therapy after a maximum treatment time of 15 months in study MS-F204EXT, and 69.5% remained on therapy after a maximum treatment time of 36 months in study MS-F203EXT. The average treatment time for all patients was 10 months in the MS-F204EXT study and 26 months in the MS-F203EXT study, both inclusive of dropouts.